CTLA4 and melanoma: Recently, some studies have indicated that increased tumor mutation loads were associated with survival benefit from both anti-CTLA-4 and anti-PD-1 therapy in multiple malignancies such as melanoma (Hugo et al., 2016), lung cancer (Rizvi et al., 2015), and esophagogastric cancer (Greally et al., 2019).